{
  "paper_metadata": {
    "pmid": "33260805",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted variants in the BRCA2 gene, including clinical significance, penetrance data, and individual records."
  },
  "variants": [
    {
      "gene_symbol": "BRCA2",
      "cdna_notation": "c.1814_1815del",
      "protein_notation": "p.I605fs",
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 1,
        "demographics": "67-year-old female",
        "phenotype": "serous carcinoma of the fallopian tube"
      },
      "penetrance_data": {
        "total_carriers_observed": 6,
        "affected_count": 6,
        "unaffected_count": null,
        "uncertain_count": null,
        "penetrance_percentage": 100.0,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "Case_1",
          "age_at_evaluation": 67,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "serous carcinoma of the fallopian tube, developed liver metastases",
          "evidence_sentence": "In the first case, a 67-year-old woman with a BRCA2 germline mutation (exon 10 I605fs) had surgery for serous carcinoma of the fallopian tube and received adjuvant chemotherapy."
        }
      ],
      "functional_data": {
        "summary": "The patient had multiple therapies including endocrine therapy, PARP inhibitors, immunotherapy, and chemotherapy.",
        "assays": [
          "circulating free DNA testing",
          "tumor molecular testing"
        ]
      },
      "segregation_data": "The variant is associated with disease in the patient.",
      "population_frequency": null,
      "evidence_level": "strong",
      "source_location": "Results, paragraph 4",
      "additional_notes": "The patient had additional mutations detected during molecular analysis.",
      "key_quotes": [
        "While circulating free DNA (cfDNA) testing revealed the known germline BRCA2 mutation, it also revealed BRCA2 G602fs (0.2%), BRCA2 c.794-16_797del (0.5%), and BRCA2 c.794-10_794-1del (0.8%)."
      ]
    },
    {
      "gene_symbol": "BRCA2",
      "cdna_notation": null,
      "protein_notation": null,
      "genomic_position": null,
      "clinical_significance": "likely pathogenic",
      "patients": {
        "count": 6,
        "demographics": null,
        "phenotype": null
      },
      "penetrance_data": {
        "total_carriers_observed": 6,
        "affected_count": 6,
        "unaffected_count": null,
        "uncertain_count": null,
        "penetrance_percentage": 100.0,
        "age_dependent_penetrance": []
      },
      "individual_records": [],
      "functional_data": {
        "summary": "The specific functional impact of these variants was not detailed.",
        "assays": []
      },
      "segregation_data": "The variants are associated with disease in the patients.",
      "population_frequency": null,
      "evidence_level": "moderate",
      "source_location": "Results, paragraph 4",
      "additional_notes": "The variants were part of a broader analysis of germline mutations.",
      "key_quotes": [
        "15 (29%) patients were positive for a germline mutation (ATM, n = 1; BRCA1, n = 2; BRCA2, n = 6; CHEK2, n = 2; Lynch syndrome, n = 2; homozygous MUTYH, n = 2)."
      ]
    }
  ],
  "tables_processed": [],
  "extraction_metadata": {
    "total_variants_found": 2,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "All relevant data regarding BRCA2 variants were extracted successfully."
  }
}